Best GLP-1 After Failing Wegovy: What to Try Next, Based on What Went Wrong

Disclosure: Ro and Sesame are commercial partners. We may earn a commission from referrals at no extra cost to you. We explain how commercial relationships affect our comparisons below. How we make money

For too little weight loss, Zepbound is our first different-medicine option to discuss when choosing the best GLP-1 after failing Wegovy. It beat standard-dose semaglutide head-to-head. Wegovy HD is another option after at least 4 weeks tolerating 2.4 mg. Side effects need a safety review—not a stronger dose. 1 2 3

If Wegovy let you down, you're not broken. In Wegovy's main trial, about 1 in 7 people with a recorded week-68 weight in the 2.4 mg group lost less than 5% of their weight. 4

But "Wegovy failed" can mean at least five different things. Each one calls for a different next step. The wrong fix can cost you months and a lot of money. Without insurance, eligible self-pay patients pay $299 to $449 per 28-day fill for Zepbound under its purchase offer, while Wegovy HD is $399 per four-pen box. Below, you'll find your situation. You'll also see the real-world number most pages leave out: how much switching added in a study of people who had already used semaglutide. 5 6 7

This page is for you if:

• You reached a standard Wegovy maintenance dose (1.7 or 2.4 mg), stayed on it about 3 months, and lost less than 5%.
• Wegovy worked for a while, then your weight stopped moving.
• Side effects kept you from reaching the full dose.
• Your insurance moved you from Zepbound to Wegovy, and it isn't working as well. Something changes on October 1, 2026 — see the insurance section.

Go somewhere else first if:

• You're under 18. Zepbound is approved only for adults. → See the teen-specific options below. 3
• You take Wegovy to lower your risk of heart attack or stroke. Talk with your heart doctor before you switch. → Best GLP-1 for heart protection
• You haven't had a treatment review at your maintenance dose. It may be too early to judge weight loss, but you do not need to wait to report side effects. → Did Wegovy really fail?
• You have Medicare. Some eligible members have a $50 option, but the rules differ from commercial insurance. → Medicare GLP-1 Bridge guide. 8
• You have severe stomach pain, vomiting you can't stop, or trouble breathing. Get medical care now. This page can wait.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Find my situation ↓

Already set on Zepbound? See Zepbound care options on Ro (sponsored)

What should you try after Wegovy? Start with what went wrong

The right next step after Wegovy depends on what went wrong. Too little weight loss, a stall after early success, side effects, and insurance problems each point to a different move. Match your experience to a row below, then read that section for the details.

Every row has a full answer further down. These are our discussion priorities—not instructions to change your medicine yourself.

Sources: prescribing information, the Barenbaum switching study, CVS Health, and manufacturer prices checked September 22, 2026. 2 3 5 6 7 9

The right GLP-1 provider isn't the same for everyone. It depends on your state, your insurance and formulary, the medication you need, your preferred form (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to explore provider options before you choose. Confirm the treatment with your clinician and the current price with the provider.

Just want the full menu of Wegovy alternatives, for any reason? See our Wegovy alternatives guide. This page is for people who already tried Wegovy.

Did Wegovy really fail, or was it too early to tell?

A useful time to review Wegovy is after about 12 weeks on your agreed maintenance dose. NIDDK guidance says that losing less than 5% of your starting weight after 12 weeks on a medication's full dose is a reason to discuss changing treatment. That is general guidance—not a Wegovy-specific rule that you must wait, stop, or switch. 10

Wegovy starts low on purpose. The dose climbs every 4 weeks to go easy on your stomach. On the standard injection schedule, 2.4 mg starts in week 17. That's why it's easy to judge Wegovy months too early. 2

Your Wegovy clock (standard schedule)

Our math: starting 2.4 mg in week 17 gives 12 completed weeks at that dose by the end of week 28—a review around week 29. That is roughly 7 months after your first shot. If your dose climb was slowed or paused, your clock moves later. If your prescriber kept you at 1.7 mg, count from when that became your ongoing dose rather than assuming everyone has the same week-29 deadline. 2 10

Who decides if Wegovy "failed"?

Two groups review your results: your prescriber and your insurance plan. A clinical decision and a coverage rule are not the same thing.

Sources: NIDDK, Wegovy criteria, and Zepbound criteria, checked September 22, 2026.

Where did you land? Compare yourself with Wegovy's big trial

In STEP 1, Wegovy's main trial, adults without diabetes were assigned to semaglutide 2.4 mg or placebo for 68 weeks. Here's how the results spread out among the 1,212 semaglutide participants with a recorded week-68 weight, not all 1,306 originally assigned to that group. 4

Our math from STEP 1's published results (New England Journal of Medicine, 2021): 100 − 86.4 = 13.6%; 86.4 − 69.1 = 17.3%; 69.1 − 50.5 = 18.6%. The last group is the reported 50.5%. People in the trial got regular counseling. These are trial results, not your odds of success. To turn a percent into pounds, try our percent vs. pounds guide. 4

Five things that can look like failure but may not be

1. You never reached your agreed maintenance dose. Wegovy's recommended standard dose is 2.4 mg. The label also allows 1.7 mg. 2
2. You haven't had a full response review yet. Use the clock above as a discussion aid, not a reason to ignore side effects. 10
3. You missed doses. After 2 or more missed injections in a row, the current Wegovy label says to restart dose escalation at a lower dose. Contact your prescriber for that plan; missed doses do not create an automatic new 12-week test. → Missed a dose? 2
4. Another medicine may be working against you. NIDDK lists reviewing medicines that can cause weight gain as one next step. 10
5. You have type 2 diabetes. Average loss in STEP 2 was 9.6% on Wegovy 2.4 mg over 68 weeks, lower than in STEP 1's group without diabetes. These were separate trials, not a personal limit on what you can lose. 4 11

Stalled vs. never really worked: two different problems

Stalled means you lost real weight, then the trend leveled off. For the discussion on this page, a stall lasting around 3 months is a reason to review the plan. Maintaining weight you've lost can still be a benefit; it isn't the same as never responding. → GLP-1 plateau guide

Never really worked means the overall loss stayed small despite an adequate treatment trial. Less than 5% after about 12 weeks on the full dose is one reason for a review—not a diagnosis you need to make yourself. 10

Why does the difference matter? One real-world study split people who switched by these two reasons. Its plateau group lost more after switching than its low-response group. You'll see the numbers in the next section. 5

Know your numbers? Write them down in your Wegovy Trial Record. You'll want them for your prescriber and your insurer.

Is Zepbound the best GLP-1 after failing Wegovy?

For too little weight loss, Zepbound is our first different-medicine option to discuss. Tirzepatide beat semaglutide 1.7 or 2.4 mg head-to-head: 20.2% vs. 13.7% average weight loss over 72 weeks. That trial did not test Wegovy HD or establish the best treatment specifically after Wegovy failed. 1

Here's the difference in plain words. Wegovy's medicine, semaglutide, copies one gut hormone called GLP-1. That's the hormone that tells your brain you're full. Zepbound's medicine, tirzepatide, copies GLP-1 plus a second hormone called GIP, which also helps with appetite and blood sugar. Two signals instead of one. 2 3

What the head-to-head trial found

In the SURMOUNT-5 trial, 751 adults with obesity, or overweight plus a weight-related health problem, and no diabetes took one drug or the other for 72 weeks. They took the highest tolerated study dose: tirzepatide 10 or 15 mg, or semaglutide 1.7 or 2.4 mg. 1

In short: about 8 in 10 people on Zepbound lost at least 10% of their weight, compared with about 6 in 10 on Wegovy's drug. Lilly, Zepbound's maker, paid for the trial, and people knew which drug they were getting. It gives a direct comparison of these doses—not a prediction of extra loss after switching. The trial was not designed to prove that one drug causes fewer side effects. 1 12

Big real-world records point the same way on average weight loss. In a 2026 study of 10,339 matched pairs of users, the greatest recorded weight loss during up to 2 years averaged 14.7% on tirzepatide and 10.8% on semaglutide. The records included several brands and forms, including diabetes products. This was not a study of switching after Wegovy failed. 13

The number most pages leave out: what switching actually added

Here's the catch. SURMOUNT-5 was not a trial of people whose Wegovy treatment had failed. Its 20.2% result starts at the trial's baseline; it is not another 20.2% promised after your Wegovy weight loss. 1

A 2026 real-world study helps fill that gap. Doctors at one clinic looked back at patient charts. Its switching analysis included 61 people who moved from semaglutide to tirzepatide because of low response or a plateau. Prior semaglutide treatment was at least 1.7 mg weekly for at least 1 month. The researchers measured weight change over the next 6 months. 5

Sources: Barenbaum et al. (2026), Jabbour et al. (2024), and SURMOUNT-5. 1 5 14

How sure can we be? Not very sure — yet. The switch study was small. It looked back at charts from one clinic and only lasted 6 months. It had no comparison group that stayed on Wegovy. The difference between 8.1% and 2.9% is useful evidence to discuss, not a number you should expect for yourself. 5

Surprises go both ways, too. A 2026 case report described a man who lost less than 5% on tirzepatide, then lost 20% after switching to semaglutide. One case cannot tell us how often that happens. It does show why a group average should not decide your whole treatment plan. 15

Our read

If Wegovy worked and then stalled, put Zepbound and Wegovy HD on your next-visit list. If Wegovy barely moved the scale, Zepbound still deserves a discussion because it is a different medicine with strong weight-loss evidence. But don't pay for a promise that switching will fix a low response. Ask your prescriber about the wider menu too. (See what if the next one doesn't work either.) 1 2 5

Who needs a different plan or a closer review before Zepbound

• You're under 18. Zepbound is approved only for adults.
• You or any family member had medullary thyroid cancer, or you have MEN 2. Zepbound is contraindicated, as is Wegovy. 2 3
• You're pregnant or planning to be. Weight-loss medicines are not a pregnancy treatment. 3 10
• You take Wegovy for heart protection and haven't talked with your cardiologist. (More in Does your health change the answer?)
• You've had a serious allergic reaction to tirzepatide or a Zepbound ingredient. Do not use it. 3

What the first weeks feel like

Zepbound's label starts treatment at 2.5 mg for 4 weeks. That's a starter dose, not a dose meant for long-term weight loss. There is no official Wegovy-to-Zepbound dose conversion, so the handoff needs a plan—not a guess based on your old dose. → How to switch from Wegovy to Zepbound 3

One honest thing before you click. Ro does not sell Zepbound for less than Lilly does. Ro lists the same Zepbound KwikPen prices as Lilly's own self-pay program: $299 to start, $399 at 5 mg, and $449 at higher doses with on-time refills. On top of that, Ro charges a membership. If the lowest total bill is your priority and you already have a doctor who will manage the switch, filling through LillyDirect avoids that extra membership fee. See how LillyDirect and Ro compare. Ro's extra fee buys care, not cheaper medicine: a clinician reviews your history, and its insurance team can submit prior-authorization paperwork for eligible commercial-plan prescriptions. 6 16 17

Does this sound like you? See Ro’s Zepbound options and start an eligibility review → (sponsored) Get started for $39, then as low as $74/month with annual plan paid upfront, or $149 month to month. Zepbound is billed separately. Ro's terms provide an initial refund if no medication is prescribed—not a refund guarantee if insurance denies coverage. Ro says you'll hear whether you're eligible within 2 days; we did not test that timeline. 16 17

Should you try Wegovy HD before switching?

Wegovy HD (semaglutide 7.2 mg) is a higher dose of the same medicine in Wegovy. The FDA approved it on March 19, 2026, for adult weight management, including obesity or overweight with a weight-related condition. The label requires at least 4 weeks tolerating 2.4 mg before an increase when more weight reduction is needed. In STEP UP, it averaged 18.7% loss versus 15.6% on 2.4 mg. Eligible self-pay patients pay $399 per 28-day box. 2 7 18 19

Think of Wegovy HD as turning up the volume, not changing the song. You stay on a medicine you already know. When the label's conditions are met, your prescriber can increase from 2.4 mg without starting semaglutide over at a starter dose. 2

STEP UP followed 1,407 adults with obesity and no diabetes. A placebo is a look-alike shot with no medicine. Novo Nordisk, Wegovy's maker, paid for the trial. The two weight-loss analyses answer different questions; neither is a prediction for a person switching after Wegovy. 19 20

The trade-offs, in plain words:

• Odd skin feelings are the big one. About 23 in 100 people on 7.2 mg had them in STEP UP, versus 6 in 100 on 2.4 mg. Gut-related side effects were also more common: 70.8% versus 61.2%. 19
• If you cannot tolerate 2.4 mg, HD isn't the next step. The label requires tolerating 2.4 mg first. 2
• It costs $50 more per four-pen box than 2.4 mg: $399 vs. $349 through the NovoCare offer. 7
• SURMOUNT-5 did not test HD against Zepbound. Comparing 18.7% in STEP UP with 20.2% in SURMOUNT-5 does not establish a winner. 1 19

Wegovy HD or Zepbound? A simple way to frame the choice

This table is our discussion framework, not a tested rule for which drug will work best. Poor tolerability calls for a safety review before either choice. 2 3 5 6 7

If you stalled after real weight loss, both are options to discuss. HD keeps you on a drug you know. Zepbound has a small study of people who switched after a plateau. Your current prescriber may be able to move you to HD without a new program. → CagriSema vs. Wegovy HD 2 5

Would Ozempic, the Wegovy pill, or compounded semaglutide work better?

A new semaglutide brand is not a proven fix for weak results on Wegovy. Ozempic and the Wegovy pill contain semaglutide, the same medicine as Wegovy. Injectable Ozempic's top dose is 2 mg, below Wegovy's standard 2.4 mg dose. Compounded versions are not FDA-approved or proven better after Wegovy. 2 21 22

Here's the trap. A new brand name can feel like a new drug. Often, it isn't.

Sources: FDA prescribing information and NIDDK. Drug doses are not interchangeable milligram for milligram across these products or forms. 2 3 10 21 23

Our rule of thumb for semaglutide brands: changing the brand changes the box, not the medicine. A different dose or form can still matter, but a new name alone is not a new way of working.

Have type 2 diabetes? Your lane is different. See the best GLP-1 after failing Ozempic and the best GLP-1 for diabetes.

About compounded GLP-1s Compounded drugs are made or altered for a patient's needs rather than sold as the FDA-approved finished product. They are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality before marketing. It says they should be used only when an FDA-approved drug can't meet a patient's medical needs. The FDA declared the national tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025; shortage-based copying is not an ongoing blanket permission. Patient-specific compounding has separate legal requirements. FDA-approved Zepbound now has self-pay prices starting at $299, so we'd compare FDA-approved options first. For the full picture, see compounded vs. name-brand GLP-1s and the current compounding rules. 6 22 24

Is a GLP-1 pill a good next step after Wegovy?

A GLP-1 pill can make sense after Wegovy when the needle, routine, or cost is the problem. A useful example is weight maintenance: in ATTAIN-MAINTAIN, people who had reached a plateau on semaglutide kept an estimated 79.3% of their earlier weight loss after 52 weeks on orforglipron, versus 37.6% on placebo. That is weight loss kept—not an extra 79.3% of body weight lost. 25

Sources: current labels, manufacturer pricing, ATTAIN-1, OASIS 4, and ATTAIN-MAINTAIN. Prices checked September 22, 2026. The separate weight-loss trials do not prove one pill is stronger. 2 7 23 25 26 27 28

ATTAIN-MAINTAIN studied people after 72 weeks in the injection trial; its main analysis focused on those who had reached a plateau. It did not test pills as a rescue for Wegovy nonresponse, and it did not compare a pill with continuing the injection. So a pill can fit when you want to keep weight off without shots. It is not a proven upgrade for weak Wegovy results. → Is Foundayo worth it? · Is the Wegovy pill worth it? · Wegovy pill dosage chart 25

What if side effects made you stop Wegovy?

Side effects don't always mean you need a new drug. Wegovy's label lets your prescriber slow the dose climb or keep you at 1.7 mg instead of 2.4 mg. If even 1.7 mg is too much, ask your prescriber to review whether to stop or choose another treatment. 2

Ways to stay on Wegovy (all in the label):

• Wait an extra 4 weeks before the next dose step.
• Stay at 1.7 mg instead of moving up to 2.4 mg.
• After 2 or more missed injections in a row, the current label says to restart dose escalation at a lower dose. Your prescriber should set the restart plan. 2

If you need to leave Wegovy:

• In the head-to-head trial, 2.7% of people quit tirzepatide because of stomach side effects, compared with 5.6% on semaglutide. That trial was not designed to prove a safety advantage. In Wegovy's own main trial, 4.5% quit for stomach reasons. 4 12
• That's encouraging, but it isn't a promise. Nausea, vomiting, diarrhea, and constipation are common with these GLP-1 medicines, pills included. 2 3 23
• Wegovy HD is not the next step while you cannot tolerate 2.4 mg. You have to handle 2.4 mg first. 2

→ GLP-1 nausea: what helps · Best GLP-1 with the least side effects

Get help now, not later Call your doctor right away if you have stomach pain that is severe or won't go away, vomiting you can't stop, or signs of dehydration such as dizziness or very little urine. Get emergency care for trouble breathing or swelling of your face, lips, tongue, or throat. These warnings come from the Wegovy and Zepbound prescribing information.

Sources: Wegovy prescribing information and Zepbound prescribing information.

Does your health change the answer?

Yes. Wegovy is FDA-approved to lower the risk of major heart events in adults with established heart disease and excess weight, and Zepbound's label does not include that approval. Zepbound is also approved only for adults. The condition being treated—and the exact Wegovy form and dose—can change the answer. 2 3

What you keep or lose by leaving Wegovy

Sources: current Wegovy and Zepbound prescribing information. The 20% heart figure is a relative reduction in cardiovascular death, nonfatal heart attack, or nonfatal stroke combined—not a 20-percentage-point drop. 2 3

On August 28, 2026, the FDA approved Mounjaro, the diabetes brand of tirzepatide, to reduce major cardiovascular-event risk in adults with type 2 diabetes at high cardiovascular risk. That approval belongs to Mounjaro, not Zepbound. 29

• Heart disease, no diabetes: Wegovy's heart approval is a real reason to stay. Talk with your cardiologist before you switch. → Best GLP-1 for heart protection
• Type 2 diabetes: Average weight loss was 9.6% on Wegovy 2.4 mg over 68 weeks in STEP 2. Do not treat the larger no-diabetes trial averages as a personal promise. If blood sugar is your main goal, a diabetes medicine may fit better. → Best GLP-1 for diabetes 11
• Teens: FDA-approved options for eligible patients ages 12 and up include Wegovy injection, Saxenda, Qsymia, and orlistat, per the NIDDK. A pediatric obesity specialist should guide any change. 10
• Sleep apnea: Zepbound's approval for moderate-to-severe obstructive sleep apnea in adults with obesity can change which indication your prescriber submits to insurance. Coverage still depends on the plan. → Best GLP-1 for sleep apnea 3
• Pregnancy: The NIDDK says not to take weight-loss medicines while pregnant or planning a pregnancy. Wegovy's label says to stop at least 2 months before a planned pregnancy. 2 10
• Thyroid cancer history: If you or any family member had medullary thyroid cancer, or you have MEN 2, Wegovy, Zepbound, and Foundayo are contraindicated. Switching won't get around it. → GLP-1 boxed warnings 2 3 23
• Other medicines or health problems: Tell the clinician about severe stomach-emptying problems, past pancreatitis, gallbladder problems, kidney disease, serious drug allergies, and any insulin or sulfonylurea use. These can change safety and monitoring. Also tell your surgical team before anesthesia or deep sedation. 2 3 23

Will insurance cover your next GLP-1 after Wegovy?

It depends on your plan's written rules, but your Wegovy history can help. Some plans require trying Wegovy first, a rule called step therapy, and a record of poor results or side effects can support a request for Zepbound. On CVS Caremark's standard commercial drug lists, Zepbound returns as a preferred option on October 1, 2026. 9 30

A few quick words first:

• Prior authorization: your plan's OK before it will pay for a drug.
• Step therapy: your plan makes you try its preferred drug first.
• Formulary exception: a request to cover a drug your plan's drug list (its formulary) normally doesn't.

If your plan made you try Wegovy first

Step therapy sounds like a wall. For you, it may be a door, because you've already taken the "step." If Wegovy didn't work or made you sick, your prescriber can use your record to ask for the next drug. That can mean a new prior authorization or a formulary exception, depending on why the plan rejected it. 30

First check the kind of denial. A drug-list exception and an employer's exclusion of all weight-loss medicines are different problems. Meeting a Wegovy step does not automatically override a benefit exclusion. → CVS Caremark Zepbound prior authorization · UnitedHealthcare step therapy · Denial decoder · Free appeal letter template 9 30

What changes on October 1, 2026

In July 2025, CVS Caremark dropped Zepbound from its main commercial drug lists and made Wegovy the preferred choice. On May 28, 2026, CVS announced that Zepbound comes back as an additional preferred option on October 1, 2026. Wegovy stays preferred too. 9

Two catches. Your employer decides whether to use the updated list, and prior authorization still applies. As of September 22, 2026, October 1 is still ahead. Ask now whether your plan is adopting the change and what your prescriber must submit; do not assume the pharmacy will automatically switch your medicine. → CVS Caremark Zepbound coverage and prior authorization 9

Your "starting weight" may be your weight before Wegovy

This one surprises people. CVS Caremark's published Zepbound criteria, protocol 6192-C, measure baseline BMI from the start of any earlier weight-loss drug when the patient is changing treatment. BMI is a number based on your height and weight. So the weight you lost on Wegovy may not count against you under those criteria. Keep a record of your weight before your first weight-loss medicine—not just today's weight. Your plan must actually use that policy. 30

If your plan stopped Wegovy at renewal

In the CVS Caremark criteria cited here, adult weight-management renewal requires at least 3 months on a stable maintenance dose plus at least 5% loss from baseline, or maintenance of that initial 5% loss. That is one plan-policy example, not a universal rule. A denial for missing the mark is useful paperwork for the next review, but it does not prove a new drug will be covered or require every switcher to lose another 5%. Get the new drug's exact initial and renewal rules. 30 31

Five questions to ask your insurer

1. "Is Zepbound on my plan's drug list for weight management?"
2. "Does it need prior authorization or a step-therapy exception?"
3. "What records do you need about my time on Wegovy?"
4. "Do you measure my BMI from before I started Wegovy?"
5. "What would my copay be?"

Medicare, Medicaid, and TRICARE

Drugmaker copay savings cards generally exclude government insurance; separate cash-pay programs and Medicare's Bridge have different rules. The Medicare GLP-1 Bridge charges $50 per monthly supply for eligible Part D members from July 1, 2026, through December 31, 2027. It includes Wegovy injection and tablets, Foundayo, and the Zepbound KwikPen—not Zepbound's other presentations. 8 32

Eligibility is not automatic. You must be at least 18, have eligible Part D coverage, and meet one of these tests at the start of GLP-1 treatment:

Your provider must certify that treatment is part of a diet-and-exercise lifestyle program and complete the required authorization. People already getting a GLP-1 through Part D are not eligible for the Bridge. For diabetes, sleep-apnea, cardiovascular, or MASH treatment that can be covered under regular Part D, check that coverage path instead. The $50 Bridge payment does not count toward your Part D out-of-pocket limit. 8 32

Moving from Wegovy to Zepbound KwikPen can keep the Bridge's $50 copay for an eligible patient, but changing drugs requires a new request. Medicaid and TRICARE use their own coverage rules. → Medicare GLP-1 Bridge guide · TRICARE and GLP-1s 8 32

Want someone else to handle the paperwork?

Ro's insurance team checks your coverage. If you need prior authorization, it submits the paperwork for you. Ro says the insurance process takes about 2 to 3 weeks. One member Ro features on its site, Hannah, said she was "thrilled to not have to fight for my coverage." (Ro notes that its featured members were paid for their testimonials.) That's a service experience, not an approval promise. Ro can't coordinate government insurance like Medicare or TRICARE. 16 17

See if your plan covers Zepbound—start a free coverage check on Ro → (sponsored) Free. Checks Ozempic, Wegovy, and Zepbound pens on commercial insurance. It does not check the Wegovy pill, Foundayo, or Zepbound KwikPen. Not for Medicare, Medicaid, or TRICARE. The free report does not submit a treatment request or write a prescription. 17 33

What will your next step cost?

Under the published self-pay offers, Wegovy 2.4 mg costs $349 per 28 days, Wegovy HD costs $399, and Zepbound costs $299 to start, then $399 to $449 with the applicable refill offer. In the 52-week examples below, switching to Zepbound adds $550 to $1,100 in medicine costs versus staying on Wegovy 2.4 mg, before care fees. These are calculations at prices checked September 22, 2026—not a locked-in quote for the coming year. 6 7

Medicine prices per fill (self-pay)

Foundayo's exact dose prices: 0.8 mg is $149. Through December 31, 2026, 2.5 mg is also $149 and 5.5 mg is $199; their regular prices are $199 and $299. The 9 mg dose is $299. The 14.5 and 17.2 mg doses are $299 under the 45-day refill purchase offer, or $349 without it. 28

Zepbound's weight-management maintenance doses are 5, 10, and 15 mg. The 7.5 and 12.5 mg steps are not listed maintenance doses. Needles for KwikPen and needles/syringes for vials can cost extra. 3 6

Sources: NovoCare's Wegovy offer, LillyDirect's Zepbound program, and Lilly's Foundayo savings terms. Checked September 22, 2026. Eligibility, taxes, supplies, and other fees can affect what you pay. 6 7 28

52-week injection budget, by path (our math)

These examples assume the listed prices remain unchanged, each injection fill lasts 28 days, and treatment continues without gaps. The last row is a cost model, not a dose schedule. Your clinician chooses the dose and time at each step. Offers can change before the modeled period ends. 2 3 6 7

Pill budgets use 30-day fills—not 28-day fills

The Foundayo example does not count temporary starter discounts, so it does not assume they last into 2027. At today's promotional prices, one fill each at 0.8, 2.5, and 5.5 mg totals $497, rather than $647 at their regular prices. That is a three-fill comparison—not a promise about which dose you'll need. 23 28

Why separate the tables? Thirteen 28-day fills cover 364 days; twelve 30-day pill fills cover 360 days. Neither is exactly a 365-day calendar year. Multiplying every "monthly" price by the same number hides the difference.

Care fees (on top of medicine)

Sources: Ro and Sesame program pages and terms, plus manufacturer pharmacy programs. Prices checked September 22, 2026. At $99 every 28 days, 13 Sesame charges would total $1,287 over 364 days. Ro's $74 figure is an annual-prepayment equivalent, not a $74 cancel-any-month plan. 6 7 16 17 34

Three price traps:

• Late refill purchases can cost more. On Zepbound 7.5 mg and up, and Foundayo 14.5 or 17.2 mg, the purchase offer requires the next qualifying purchase within 45 days of receiving the previous fill. Do not change your prescribed use just to meet an offer. 6 28
• "As low as $25" has strings. The covered-insurance offers discussed here require eligible commercial coverage. Wegovy's covered-insurance offer has a maximum saving of $100 per month; a remaining copay can exceed $25. Government plans are excluded from these copay cards. 7 28
• Starter prices aren't forever prices. Look at what you'll pay at the dose you'll stay on.

→ Cheapest Zepbound without insurance · NovoCare prices, dose by dose · GLP-1 cost calculator

Do you need a new provider to switch?

Not always. If your current prescriber knows your history and will manage a switch, start there. A telehealth program is worth it when you don't have a prescriber who will help, you want someone to handle insurance paperwork, or you want to pick a clinician yourself.

Sources: published provider and manufacturer program information, checked September 22, 2026. These are service features, not a head-to-head test of clinical care. 6 7 16 17 28 34

Why Ro is our first provider to compare for a guided, insured switch

Ro puts the hard parts in one place. The Ro Body membership includes an insurance concierge, unlimited messaging with a provider, side-effect and dose support, and 1:1 health coaching. Ro says you'll learn whether you're eligible within 2 days, and people paying cash can take a first dose in less than a week. Those are Ro's stated timelines, not response times we measured. Ro also shows LegitScript certification on its site. 16

A few details matter here. At Ro, the Zepbound KwikPen, the Wegovy pill, and Foundayo are cash-pay only. Commercial insurance can be used for eligible Wegovy and Zepbound pen prescriptions. And as we said above, Ro doesn't lower the medicine price; you're paying for the care. Ro's terms describe medical-team business hours and message review within 48 hours, not an on-call emergency service. See Ro's plans and full pricing → (sponsored) 16 17

When Sesame fits better

Sesame is a marketplace. You browse clinicians and choose one yourself. That can matter after one drug didn't work and you want a clinician whose approach fits you. Its monthly program is advertised at $99 and bills every 28 days; the annual plan is advertised at $59/month equivalent, with medicine billed separately. Some clinicians charge more. The program also lists help with medication prior authorization. 34

"Thorough assessment. Provided the care I needed," wrote LW Whitehorn in a September 21, 2026 Trustpilot review of Sesame. That's one person's service experience, not a medical result. 35

Want to pick your own clinician? Compare Sesame providers and plan terms → (sponsored)

How Ro and Sesame compare on the RX Index Score pillars

These are written notes, not numeric scores. → Ro review · Sesame review

Sources: provider-stated features and terms. 16 17 34

What should you bring to your next appointment?

Bring a one-page record of your time on Wegovy. Include your starting weight, each dose and how long you took it, missed doses, side effects, and why you want a change. It helps your prescriber choose the next step faster, and it gives your insurer the proof many plans ask for.

Your Wegovy Trial Record (print this or copy it into your notes app)

• Weight before I started Wegovy: ______ lb (date: ______)
• Earlier weight-loss medicine before Wegovy, if any, and my weight before it: ______
• My height: ______ (so my prescriber can figure my BMI)
• Exact Wegovy form (shot or pill): ______
• Highest dose I reached: ______ mg, starting on ______
• Weeks at that dose: ______
• Weight at the response review my prescriber scheduled: ______ lb (date: ______)
• Weight today: ______ lb
• Percent lost: ______% (starting weight minus today's weight, divided by starting weight, times 100. Example: 230 − 221 = 9, and 9 ÷ 230 = 3.9%.)
• Missed doses or gaps (when, how long): ______
• Side effects (what, when, at which dose): ______
• Why I want a change: ☐ lost too little ☐ stalled ☐ side effects ☐ insurance ☐ cost ☐ tired of shots
• My insurance, and any denial letters: ______
• What I can spend per month: ______
• Other medicines, major health conditions, or pregnancy plans to review: ______
• My main question: Should we continue, adjust the dose, switch, or try something different?
• Before I change anything, please confirm: the last old dose, first new dose, refill access, follow-up date, and what symptoms need a call.

Switching basics (your prescriber runs this part)

• Never take two GLP-1 medicines at once. Zepbound's label advises against using it with another GLP-1. 3
• Zepbound's labeled starting dose is 2.5 mg for 4 weeks. There's no official Wegovy-to-Zepbound dose conversion. 3
• If you take birth control pills, Zepbound's label says to switch to a non-pill method or add a barrier method for 4 weeks after starting and after each dose increase. 3
• Using insurance? Ask whether the new drug needs a new prior authorization; do not assume your Wegovy approval transfers. 30 31

→ How to switch from Wegovy to Zepbound · Switching from semaglutide to tirzepatide · Zepbound dose chart

What if your next GLP-1 doesn't work either?

You still have options. The NIDDK lists these next steps when a weight-loss medicine isn't working: a different medicine, a structured lifestyle program, changes to other medicines that can cause weight gain, and a referral to a weight-loss surgeon. Newer drugs like CagriSema and retatrutide are not FDA-approved yet. 10 22 36

• A different kind of medicine. FDA-approved non-GLP-1 options include phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), and orlistat. They work in different ways. A different mechanism or safety profile may matter more than another GLP-1 switch. → Contrave vs. GLP-1 10
• A specialist-directed combination. Combining a GLP-1 with another weight-loss medicine may be off-label, meaning the specific use has not been FDA-approved. It is not a do-it-yourself next step, and it does not mean taking two GLP-1s together. 2 3 10
• Weight-loss surgery. For some people, surgery is the next step. → GLP-1 vs. bariatric surgery
• An obesity medicine specialist. A doctor who focuses on weight can look at the whole picture, not just the next prescription.
• What's coming. CagriSema combines semaglutide with cagrilintide, which acts like another hormone called amylin. Retatrutide acts on three hormone receptors. Neither is an FDA-approved treatment option as of September 22, 2026. → CagriSema FDA status · Retatrutide availability 22 36

Skip "research peptide" websites. The FDA warns that products sold "for research use" aren't meant for people and may be harmful. 22

How did we check the facts on this page?

We checked the current drug labels, original study reports and abstracts, and the drugmakers' and providers' published price pages. Our recommendations are editorial judgments built on those facts. We earn commissions from some providers, but a commission does not change a trial result, an approved use, or a plan's written rule.

What we actually verified (September 22, 2026)

• Prices: NovoCare's Wegovy pen, Wegovy HD, and pill offers; LillyDirect's Zepbound prices; Lilly's Foundayo dose-specific offers; and Ro's and Sesame's published program prices.
• Provider terms: Ro's refund and 48-hour cancellation terms, and Sesame's plan prices and 28-day billing.
• Drug labels: standard maintenance doses, Wegovy HD eligibility, missed-injection instructions, approved uses by form, and Zepbound and Foundayo contraceptive guidance.
• Studies: SURMOUNT-5, STEP 1, STEP 2, STEP UP, OASIS 4, ATTAIN-1, ATTAIN-MAINTAIN, the 2024 prospective switching study, and the 2026 real-world reports cited below.
• Guidance: NIDDK's general recommendation to review a medication when loss is below 5% after 12 weeks on its full dose—not a Wegovy-specific stop rule.
• Insurance: CVS Health's May 28, 2026 announcement, published protocols 6192-C and 4774-C, and CMS/Medicare Bridge rules. The dates of this check are not claimed publication dates for those protocols.
• Our own math: 364-day injection budgets, 360-day pill budgets, the Foundayo three-fill comparison, STEP 1 percentage bands, and the standard-schedule week-29 example.

What we did not check: your plan's individual decision, availability in your state, a completed checkout, prescribing approval, actual provider response times, personal treatment results, or the matching tool's results for your case. Trial averages are not personal forecasts.

Provider-stated vs. checked on this page

Checked September 22, 2026. Sources: LillyDirect, Ro, Ro terms, and Sesame.

The original work here is the after-Wegovy comparison, the matched billing-period calculations, and the Trial Record. We did not conduct a clinical trial or test either provider as a patient.

How we decide. The RX Index is independent guidance for choosing your GLP-1 path. We judge options on the RX Index Score's five pillars: clinical legitimacy, care quality, transparency, access, and cost. Evidence comes first. What a provider pays us only breaks ties when the evidence is equal. Compounded products are never ranked on this page. → Our methodology · Editorial standards

Who published this. The RX Index. See something wrong? Tell us. We fix errors and note the change.

Frequently asked questions

What is the best GLP-1 after failing Wegovy?

For too little weight loss, Zepbound is our first different-medicine option to discuss. It beat semaglutide 1.7 or 2.4 mg head-to-head, 20.2% vs. 13.7% average loss over 72 weeks. Wegovy HD is another option after at least 4 weeks tolerating 2.4 mg when more reduction is needed. Neither result proves the best choice for every person after Wegovy. 1 2

How long should you try Wegovy before switching?

A useful review point is about 12 weeks on your agreed maintenance dose. NIDDK's general guidance says loss below 5% after 12 weeks on a medication's full dose is a reason to discuss a change. For someone starting 2.4 mg in week 17, that review falls around week 29. Side effects or other safety concerns need attention sooner. 2 10

What percentage of people don't respond to Wegovy?

In STEP 1, 13.6% of the semaglutide group's participants with a recorded week-68 weight—about 1 in 7—had lost less than 5%. That is not the percentage of every person who starts Wegovy, nor proof of permanent nonresponse. STEP 1 excluded people with diabetes. 4

Is Zepbound stronger than Wegovy?

At the doses tested in SURMOUNT-5, tirzepatide produced more average weight loss: 20.2% vs. 13.7% over 72 weeks. About twice as many reached at least 25% loss. The semaglutide doses were 1.7 or 2.4 mg—not Wegovy HD 7.2 mg. 1

Will Zepbound work if Wegovy didn't work for me?

It can help, but the available switching evidence cannot predict your result. In the 2026 one-clinic study, the 28-person plateau group lost 8.1% after switching over 6 months; the 33-person low-response group lost 2.9%. Those are small observational groups, not a randomized test of what you should take next. 5

Is Wegovy HD or Zepbound better after a plateau?

The evidence cited here does not compare them directly. Wegovy HD averaged 18.7% loss vs. 15.6% on 2.4 mg in STEP UP and requires at least 4 weeks tolerating 2.4 mg first. The small switching study supports discussing Zepbound after a plateau, but does not establish that it beats HD. 2 5 19

Can I switch from Wegovy to Zepbound right away?

Your prescriber sets the timing. Never take both at once. Zepbound's labeled starting dose is 2.5 mg for 4 weeks, and there's no official dose conversion from Wegovy. Ask for the dates and doses in writing before the handoff. 3

Will Ozempic work if Wegovy didn't?

There is no evidence here that changing to Ozempic fixes weak Wegovy results. Injectable Ozempic contains the same drug, semaglutide, and its top injection dose is 2 mg versus Wegovy's standard 2.4 mg. Ozempic has diabetes-related approvals, not a weight-loss indication. 2 21

Does Zepbound cause fewer side effects than Wegovy?

In SURMOUNT-5, fewer people quit tirzepatide over stomach side effects: 2.7% vs. 5.6%. But the trial was not designed to prove a safety advantage, and both medicines can cause nausea and other gut problems. Switching doesn't guarantee you'll feel better. 12

Will insurance cover Zepbound if I tried Wegovy first?

It depends on your plan's written rules. A record showing Wegovy didn't work, or caused side effects, can support a prior authorization or formulary exception. On CVS Caremark's standard commercial lists, Zepbound returns as a preferred option on October 1, 2026, if your employer adopts the change. 9 30

How much does it cost to switch from Wegovy to Zepbound without insurance?

The cited self-pay offer is $299 for the first 28-day 2.5 mg fill, $399 at 5 mg, and $449 at higher doses with the required refill timing. At unchanged prices, our 52-week examples add $550 to $1,100 versus continuing Wegovy 2.4 mg. That excludes care fees and is not a guaranteed year-long price. 6 7

Does no weight loss on Zepbound 2.5 mg mean it isn't working?

No. Zepbound 2.5 mg is a starter dose, not a maintenance dose. Ask your prescriber when to review your response at the dose chosen for ongoing treatment. Do not raise the dose yourself to chase an early result. 3 10

Is compounded tirzepatide a good option after Wegovy?

Compounded drugs are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality. With FDA-approved Zepbound now sold at self-pay prices starting at $299, we'd compare FDA-approved options first. 6 22

Should I buy retatrutide or "research peptides" online?

No. Retatrutide is not FDA-approved. The FDA warns that products sold "for research use" are of unknown quality and may be harmful. Lilly says its investigational retatrutide is available only through its clinical trials—not through consumer peptide sellers. 22 36

I take Wegovy for my heart. Should I switch?

Talk to your heart doctor first. Wegovy is FDA-approved to lower the risk of heart attack, stroke, and heart-related death in adults with heart disease and excess weight. Zepbound doesn't carry that approval. 2 3

Will I regain weight when I switch?

Some regain can happen after stopping a weight-loss medicine, but that does not tell us exactly what happens during a planned switch. Zepbound begins with a starter dose, so arrange the timing, follow-up, and refill access with your prescriber. Do not overlap medicines to avoid a gap. → What happens when you stop Wegovy 3 10

Still not sure which GLP-1 program is right for you? Take our free matching quiz. → Find My GLP-1 Path

This page is for information only and is not medical advice. Decisions about starting, stopping, switching, or dosing any medicine should be made with a licensed clinician. Prices and program terms change. Confirm them with the provider before you pay.

Sources

Medical claims above use prescribing information, original studies, or agency guidance. Provider prices, features, and timelines are identified as published terms—not patient testing. Dynamic prices and policies were checked September 22, 2026.

1. SURMOUNT-5: tirzepatide versus semaglutide (NEJM, 2025)
2. Wegovy prescribing information: dosing, approved uses, warnings, and missed doses
3. Zepbound prescribing information
4. STEP 1: once-weekly semaglutide in adults with overweight or obesity (NEJM, 2021)
5. Barenbaum et al.: Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide (Obesity, 2026)
6. LillyDirect: Zepbound dose prices and purchase-offer terms
7. NovoCare: Wegovy injection, HD, and pill savings terms
8. CMS: Medicare GLP-1 Bridge
9. CVS Health: expanded GLP-1 coverage announcement, May 28, 2026
10. NIDDK: prescription medications to treat overweight and obesity
11. STEP 2: semaglutide in adults with overweight or obesity and type 2 diabetes (Lancet, 2021)
12. Lilly: detailed SURMOUNT-5 results and study limitations, May 11, 2025
13. Weight-loss dynamics with tirzepatide versus semaglutide (PNAS Nexus, 2026)
14. Jabbour et al.: Switching to Tirzepatide 5 mg From GLP-1 Receptor Agonists—first 12 weeks (2024)
15. Case report of different responses to tirzepatide and semaglutide (JCEM Case Reports, 2026)
16. Ro: medication menu, membership pricing, service features, and compensated member testimonials
17. Ro: terms of use, including Ro Body billing, refunds, cancellation, and clinical support
18. FDA: Wegovy HD approval, March 19, 2026
19. STEP UP: semaglutide 7.2 mg versus 2.4 mg and placebo (Lancet Diabetes & Endocrinology, 2025)
20. Novo Nordisk: STEP UP results under both analysis methods, January 17, 2025
21. Ozempic injection prescribing information
22. FDA: concerns with unapproved GLP-1 drugs and research-labeled products
23. Foundayo prescribing information
24. FDA: compounding policies following GLP-1 shortage resolution
25. ATTAIN-MAINTAIN: oral orforglipron after injectable treatment (Nature Medicine, May 13, 2026)
26. Lilly: Foundayo approval, availability, and ATTAIN-1 analysis results, April 9, 2026
27. OASIS 4: oral semaglutide 25 mg (NEJM, 2025)
28. Lilly: Foundayo dose prices, temporary discounts, and purchase-offer terms
29. Lilly: FDA approval of Mounjaro cardiovascular-risk indication, August 28, 2026
30. CVS Caremark: Zepbound prior-authorization protocol 6192-C
31. CVS Caremark: Wegovy prior-authorization protocol 4774-C
32. Medicare.gov: weight-loss drugs and Bridge eligibility
33. Ro: free GLP-1 Insurance Coverage Checker and its scope
34. Sesame: online weight-loss program, billing, and refund terms
35. Trustpilot: LW Whitehorn’s Sesame service review, September 21, 2026
36. Lilly: what to know about investigational retatrutide